Characterisation of the anti-inflammatory pathway targeted by chaperonin 10 (Cpn10)

伴侣蛋白 10 (Cpn10) 靶向抗炎途径的表征

• 批准号: LP0990480
• 负责人: Prof J. Alejandro Lopez
• 金额: $ 22.44万
• 依托单位: Griffith University
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-07-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP0990480
• 关键词: Characterisation; anti; inflammatory; pathway; targeted

Diseases associated with excessive or inappropriate inflammation represent an enormous socioeconomic burden, and there is currently an urgent need to identify new targets for the development of more efficacious and safe treatments. This research seeks to provide such targets. The research may also lead to improvements in chaperonin 10 (Cpn10) treatment, which has already showing marked success in chronic inflammatory disease trials. Importantly, Cpn10 appears to be anti-inflammatory rather than immunosuppressive; a critical advantage over many current anti-inflammatory interventions. Immunosuppression can lead to increased infections, which can have serious consequences, especially in elderly patients.

与过度或不适当的炎症相关的疾病代表了巨大的社会经济负担，目前迫切需要确定新的靶点以开发更有效和安全的治疗方法。本研究旨在提供这些目标。这项研究还可能导致伴侣蛋白10（Cpn 10）治疗的改善，该治疗已经在慢性炎症性疾病试验中取得了显着的成功。重要的是，Cpn 10似乎是抗炎的，而不是免疫抑制;这是目前许多抗炎干预措施的关键优势。免疫抑制可能导致感染增加，这可能会产生严重后果，特别是在老年患者中。